A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers

NCT02908906 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

413

Enrollment

INDUSTRY

Sponsor class

Conditions

Neoplasms

Interventions

DRUG: JNJ-63723283

Sponsor

Janssen Research & Development, LLC